Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
10.1016/j.apsb.2020.05.004
- Author:
Tingting JIANG
1
;
Guan WANG
1
;
Yao LIU
1
;
Lu FENG
1
;
Meng WANG
1
;
Jie LIU
1
;
Yi CHEN
2
;
Liang OUYANG
1
Author Information
1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
2. State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
- Publication Type:Review
- Keywords:
AFAP1, actin filament-associated protein 1;
AML, acute myeloid leukemia;
ARHGEF2, Rho/Rac guanine nucleotide exchange factor 2;
BCAN, brevican;
BDNF, brain-derived neurotrophic factor;
BTBD1, BTB (POZ) domain containing 1;
CDK-2, cyclin-dependent kinase 2;
CR, complete response;
CRC, colorectal cancer;
CTCs, sequencing of circulating tumor cells;
DFG, Asp-Phe-Gly;
DOR, durable objective responses;
ETV6, ETS translocation variant 6;
EWG, electron-withdrawing group;
FDA, U.S. Food and Drug Administration;
FISH, fluorescence in situ hybridization;
GBM, glioblastoma multiforme;
HNSCC, head and neck squamous cell carcinoma;
HTS, high-throughput screening;
ICC, intrahepatic cholangiocarcinoma;
IG-C2, Ig-like C2 type I;
LMNA, lamin A/C;
MASC, mammary analogue secretory carcinoma;
MPRIP, myosin phosphatase Rho interacting protein;
NACC2, NACC family member 2;
NCCN, National Comprehensive Cancer Network;
NFASC, neurofascin;
NGF, nerve growth factor;
NGS, next-generation sequencing of tumor tissue;
NSCLC, non-small cell lung cancer;
NT3, neurotrophin-3;
NTRK fusion cancer;
NTRK, neurotrophic receptor tyrosine kinase;
Neurotrophic receptor tyrosine kinase fusions;
OAK, osteoarthritis of the knee;
ORR, overall response rate;
PAN3, poly(A) nuclease 3;
PPL, periplakin;
PROTAC proteolysis targeting chimera, QKI;
RABGTPase activating protein 1-like, RFWD2;
RTK, receptor tyrosine kinase;
SAR, structure–activity relationship;
SBC, secretory breast carcinoma;
SCYL3, SCY1 like pseudokinase 3;
SQSTM1, sequestosome 1;
Small-molecule inhibitor;
TFG, TRK-fused gene;
TP53, tumor protein P53;
TPM3, tropomyosin 3;
TPR, translocated promoter region;
TRIM24, tripartite motif containing 24;
TRK, tropomyosin receptor kinase;
Tropomyosin receptor kinase;
VCL, vinculin;
VEGFR2, vascular endothelial growth factor receptor 2;
quaking I protein, RABGAP1L;
ring finger and WD repeat domain 2, E3 ubiquitin protein ligase
- From:
Acta Pharmaceutica Sinica B
2021;11(2):355-372
- CountryChina
- Language:English
-
Abstract:
Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (
